Want to see NDRA full AI Analyst Report?
ENDRA Life Sciences (NDRA) Stock Statistics & Valuation Metrics
Total Valuation
ENDRA Life Sciences has a market cap or net worth of $7.12M. The enterprise value is $1.95M.
- Market Cap
- $7.12M
- Enterprise Value
- $1.95M
Share Statistics
ENDRA Life Sciences has 1,499,838 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,499,838
- Owned by Insiders
- 26.90%
- Owned by Institutions
- 3.61%
Financial Efficiency
ENDRA Life Sciences’s return on equity (ROE) is -3.11 and return on invested capital (ROIC) is -178.30%.
- Return on Equity (ROE)
- -3.11
- Return on Assets (ROA)
- -1.82
- Return on Invested Capital (ROIC)
- -178.30%
- Return on Capital Employed (ROCE)
- -1.86
- Revenue Per Employee
- 0
- Profits Per Employee
- -702.74K
- Employee Count
- 10
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of ENDRA Life Sciences is -0.76. ENDRA Life Sciences’s PEG ratio is -0.01.
- PE Ratio
- -0.76
- PS Ratio
- 0.00
- PB Ratio
- 1.01
- Price to FCF
- -0.92
- Price to Operating Cash Flow
- -1.32
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, ENDRA Life Sciences had revenue of 0 and earned -7.03M in profits. Earnings per share was -8.93.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -5.76M
- Pretax Income
- -7.03M
- Net Income
- -7.03M
- EBITDA
- -6.87M
- Earnings Per Share (EPS)
- -8.93
Cash Flow
In the last 12 months, operating cash flow was -4.82M and capital expenditures -3.02M, giving a free cash flow of -7.84M billion.
- Operating Cash Flow
- -4.82M
- Free Cash Flow
- -7.84M
- Free Cash Flow per Share
- -5.92
Dividends & Yields
ENDRA Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -110.30%
- Earnings Yield
- -94.27%
Stock Price Statistics
- Beta
- 1.81
- 52-Week Price Change
- -8.57%
- 50-Day Moving Average
- 5.47
- 200-Day Moving Average
- 4.81
- Relative Strength Index (RSI)
- 43.23
- Average Volume (3m)
- 30.80K
Important Dates
ENDRA Life Sciences upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 17, 2026
- Next Earnings Date
- Nov 16, 2026
- Ex-Dividend Date
- ―
Financial Position
ENDRA Life Sciences as a current ratio of 1.29, with Debt / Equity ratio of 21.78%
- Current Ratio
- 1.29
- Quick Ratio
- 1.29
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.04
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, ENDRA Life Sciences has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
ENDRA Life Sciences EV to EBITDA ratio is -0.78, with an EV/FCF ratio of -0.74.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.78
- EV to Free Cash Flow
- -0.74
- EV to Operating Cash Flow
- -1.20
Balance Sheet
ENDRA Life Sciences has $1.74M in cash and marketable securities with $429.27K in debt, giving a net cash position of $1.31M billion.
- Cash & Marketable Securities
- $1.74M
- Total Debt
- $429.27K
- Net Cash
- $1.31M
- Net Cash Per Share
- $0.87
- Tangible Book Value Per Share
- $4.77
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for ENDRA Life Sciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 98.17%
Scores
- Smart Score
- ―
- AI Score
- 51
